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Fouad Amraoui1*†, Sarah Bos1†, Liffert Vogt2 and Bert-Jan van den Born1Abstract
Background: Malignant hypertension is frequently complicated by renal insufficiency. Although the survival of this
hypertensive emergency has improved, recent data on renal outcome and its predictors are lacking. We assessed
renal outcome and its predictors in patients with malignant hypertension.
Methods: Retrospective analysis of patients admitted with malignant hypertension in Amsterdam, the Netherlands
between August 1992–January 2010. Follow-up data on vital status, renal function and blood pressure (BP) were
obtained from the outpatient department and from general practitioners. The primary composite endpoint was
end-stage renal disease (ESRD) defined as the start of kidney replacement therapy (KRT) or≥ 50% decline of
estimated glomerular filtration rate (eGFR). The secondary endpoint was all cause mortality.
Results: A total of 120 patients admitted with malignant hypertension were included. After a median follow-up
period of 67 months (IQR 28 to 108 months) the primary endpoint was reached by 37 (31%) patients, whereas 18
patients (15%) reached the secondary endpoint. Twenty-nine (24%) patients started KRT and 8 patients (7%) had an
eGFR decline≥ 50%. After the acute phase (> 3 months after admission), initial serum creatinine and follow-up BP
were the main predictors of future ESRD with hazard ratios of 6.1 (95% CI, 2.2–17) for patients with initial serum
creatinine≥ 175 μmol /L and 4.3 (95% CI, 1.4–14) for patients with uncontrolled hypertension.
Conclusions: Progressive renal function decline leading to ESRD remains a major threat to patients with malignant
hypertension. BP control during follow-up was an important modifiable predictor of renal outcome.
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Malignant hypertension is a hypertensive emergency
usually defined by the presence of severe hypertension
in combination with ischemic retinal changes consistent
with grade III or IV hypertensive retinopathy according
to the Keith, Wagener and Barker classification [1]. Ma-
lignant hypertension is frequently complicated by renal
dysfunction [2,3]. In most cases this is secondary to ma-
lignant hypertension with renal biopsy specimens typic-
ally showing acute ischemic changes secondary to
medial hypertrophy, intimal hyperplasia and fibrinoid
necrosis of small arteries and arterioles [4]. Although the* Correspondence: f.amraoui@amc.nl
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reproduction in any medium, provided the orsurvival of malignant hypertension has considerably
improved with the advent of antihypertensive therapy,
end-stage renal disease (ESRD) remains a significant
cause of morbidity and mortality [5,6]. Depending on
the setting and patient characteristics between 18% and
41% of patients may require kidney replacement therapy
(KRT) during the acute phase [6,7].
One would expect that because of advances in the
awareness, treatment and control of hypertension in the
population at large the incidence of malignant hyperten-
sion and its renal complications would have declined.
However, we and others have shown that malignant
hypertension remains relatively common in large multi-
ethnic communities and in urban sub-Saharan African
populations. In the Netherlands, the relative contribu-
tion of malignant hypertension to the total number of
patients starting KRT has increased by 40% in the pastl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and Transplant Association and the US Renal Data Sys-
tem show that hypertension is an important cause of
ESRD, but the role of hypertensive crises are not speci-
fied [9,10].
Previous studies have demonstrated recovery from
acute renal dysfunction in some patients with malignant
hypertension and ESRD [11,12]. However, data concern-
ing long-term renal outcome are limited. Moreover, the
influences of modifiable predictors such as blood pres-
sure (BP) control have not been established. In this
study, we aimed to assess long-term renal outcome and
predictors of ESRD and renal function decline in
patients with malignant hypertension.
Methods
Included were patients presenting with malignant hyper-
tension at a large teaching hospital, serving a multi-
ethnic community in Amsterdam, the Netherlands.
Patients were recruited between August 1992 and
January 2010. The methods for the selection strategy
have been previously described [6]. Briefly, the hospital
database, in which the diagnosis at discharge is recorded
according to the International Classification of Diseases
codes (ICD) was searched. All charts of patients admit-
ted with the diagnosis ‘essential malignant hypertension’
(ICD 401.0), ‘secondary malignant hypertension’ (ICD
405.09), ‘hypertension with cardiac disease/ malignant’
(ICD 402.0), ‘hypertension with kidney disease/malignant’
(ICD 403.0) and ‘hypertensive encephalopathy’ (ICD
437.2), were reviewed for the WHO criteria of malignant
hypertension (i.e. diastolic BP≥ 120 mmHg and presence
of grade III or IV hypertensive retinopathy [1]. To iden-
tify the presence of registration errors, computer data
of all patients discharged with the diagnosis ‘essential
hypertension’ (ICD 401.9) were also analyzed which
showed the presence of one patient with malignant
hypertension. Hereafter, we subjected our selection strat-
egy to a sensitivity analysis by searching the emergency
room archives for patients fulfilling the clinical criteria
for malignant hypertension in a sample of 3 different
years, with each year randomly selected from a period of
5 consecutive years between 1992-2008.
Excluded were patients < 18 years, pregnant women
and patients who were already on dialysis before admis-
sion and patients referred from elsewhere. This study
was performed in adherence with the Declaration of
Helsinki. The Ethics Committee in our hospital decided
approval was not required.
Definitions and analyses
Follow-up and outcome data were obtained from the
outpatient department and from general practitioners.
The primary endpoint was ESRD defined as a compositeof the start of permanent KRT or a 50% reduction in
eGFR during follow-up. All cause mortality was assessed
as secondary endpoint. Because both recovery and de-
terioration of renal function occur frequently during the
initial treatment of malignant hypertension [6], renal
outcome data were censored during the first 3 months
following admission. Change in eGFR was calculated as
the difference between first serum creatinine 3 months
after admission and last available serum creatinine dur-
ing follow-up. For calculating eGFR, the Modification of
Diet in Renal Disease (MDRD) formula was used [13].
Vital status of patients who were lost to follow-up was
assessed by inquiry of the municipal administration
registries.
Ethnicity was defined as self-reported black or self-
reported white. Black participants were mainly from
sub-Saharan Africa and from Surinam or the Dutch
Antilles. Secondary causes of malignant hypertension
were reported as present in case of any medical con-
dition or therapy that could be related to the develop-
ment of this type of hypertensive emergency.
Thrombotic microangiopathy (TMA) was defined as 1)
thrombocytopenia (platelet count < 150 x10E9/L) to-
gether with either an elevated lactate dehydrogenase
(LDH ≥ 220 U/L) or the presence of fragmentocytes
and 2) resolution of these parameters with BP lowering
therapy. Macroalbuminuria was defined as urinary pro-
tein excretion greater than 300 mg/24-h, > 200 mg/L
in spot urine or 2+ for dipstick proteinuria. Left ven-
tricular hypertrophy was considered present when
detected by a cardiologist on cardiac ultrasound (left
ventricular wall thickness > 11 mm) or by ECG as
defined by the Sokolow-Lyon criteria. Mean follow-up
BP was defined as the average of three BP recordings
starting with the first measurement 3 months after ad-
mission. The second BP recording was the measure-
ment closest to the median of the follow-up period
and the third recording was defined as the last avail-
able follow-up BP value. Blood pressure was consid-
ered to be adequately controlled if the average of all
measurements was < 140/90 mmHg.
Statistical analysis
Data are expressed as mean +/- standard deviation (SD)
when normally distributed and as median and interquar-
tile range (IQR) when distribution was skewed. Frequen-
cies and percentages are given for categorical variables.
Between group differences were assessed by t-test for
parametric and Mann–Whitney U test for non-
parametric distributions. Chi-square analysis was used
for categorical variables. Cox proportional hazard ana-
lysis was used to assess renal outcome predictors during
follow-up. First, single variables with a pathophysio-
logical relevance that had a significant association with
Table 1 Baseline characteristics of 120 consecutive
patients with malignant hypertension
Baseline characteristics
Male, n (%) 83 (69)
Age, mean (SD) 44 (12)
Black, n (%) 57 (48)
Systolic blood pressure (mmHg), mean (SD) 230 (23)
Diastolic blood pressure (mmHg), mean (SD) 145 (17)
Previous hypertension, n (%) 65 (54)
Use of anti-hypertensive medication, n (%) 39 (33)
Secondary cause of malignant hypertension, n (%) 25 (21)
Serum creatinine at admission (μmol /L), median (IQR) 175 (104–402)
Thrombotic microangiopathy, n (%) 36 (30)
Hypertensive encephalopathy 11 (9)
Retinopathy grade IV, n (%) 66 (55)
Left ventricular hypertrophy, n (%) 95 (79)
Macroalbuminuria, n (%) 66 (55)
Diabetes mellitus type 2, n (%) 6 (5)
Current smoker, n (%) 39 (33)
*IQR indicates interquartile range.
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a backward elimination method was used in which the
variable with the smallest partial correlation with the
dependent variable was removed first. Hazard ratios
(HR) and 95% confidence intervals (CI) were calculated.
Finally, significant variables were tested for interaction.
For statistical analyses, SPSS software was used (Statis-
tical Package for the Social Sciences, version 18.0, Inc.
Chicago, Illinois, USA). P values were considered to in-
dicate a significant difference if P < 0.05.
Results
Baseline characteristics
A total of 168 patients were identified via the hospital
database search. Of these patients, 120 fulfilled the
WHO criteria of malignant hypertension and could be
included in the study (Figure 1). A sensitivity analysis
showed that no patients who visited the emergency
room with malignant hypertension in 3 randomly
selected years between 1992-2008 were missed.
Baseline characteristics are summarized in Table 1.
Median serum creatinine at admission was 175 μmol /L
(IQR 104-402 μmol /L). Patients with serum creatinine
≥ 175 μmol /L were more often black (59% vs. 36%,
P= 0.01) and had higher systolic (235 vs. 225 mmHg,
P= 0.03) and diastolic BP values (148 vs. 141 mmHg,
P= 0.04). These patients more frequently displayed
TMA (51% vs. 9%, P < 0.001), macroalbuminuria (92%
vs. 53%, P < 0.001) and left ventricular hypertrophy (89%
vs. 70%, P= 0.01). There was no difference in age, sex,
severity of retinopathy or the presence of primary renal
and renovascular disease. At the start of follow-up
(3 months after admission) median eGFR was 41 ml/
min/1.73 m2 (IQR 20-68 ml/min/1.73 m2).Figure 1 Patient selection. HRP indicates hypertensive retinopathy.Primary renal disease could be identified in 9 patients
(8%), whereas renovascular disease could be identified in
7 patients (6%). Primary renal diagnoses included biopsy
proven membranoproliferative glomerulonephritis (3
patients), IgA nephropathy (3 patients) and renal in-
volvement of systemic scleroderma (1 patient). Polycystic
kidney disease (1 patient) and reflux nephropathy (1 pa-
tient) were diagnosed radiologically. Renovascular dis-
eases included renal artery stenosis (4 patients), renal
artery obstruction (1 patient), renal infarction (1 patient)
and renovascular abnormalities secondary to polyarteri-
tis nodosa (1 patient).
Renal outcome and mortality
After a median follow-up of 67 months (IQR 28–
108 months), 31% reached the primary composite end-
point, 29 patients (24%) started KRT, whereas 8 patients
(7%) had an eGFR decline ≥50% compared to baseline.
Sixteen patients (13%) required haemodialysis within
3 months after admission and this could be discontinued
in 2 patients within this period. Of the 14 patients who
reached the primary endpoint within 3 months after ad-
mission, 10 patients were black and 4 were white
(P= 0.06). The proportion of patients developing ESRD
was not significantly different between those having pri-
mary malignant hypertension and those with primary
renal or renovascular disease (24% vs. 38% respectively,
P= 0.18). A total of 18 (15%) patients died during fol-
low-up, none of the patients died within 3 months after
admission. Death was caused by cardiovascular events
Figure 2 ESRD in patients with malignant hypertension having
blood pressure <140 / 90 mmHg and ≥140 / 90 mmHg during
follow-up. Kaplan-Meier survival plot of ESRD during follow-up.
ESRD was defined as a composite of the start of kidney replacement
therapy or a 50% reduction in eGFR.
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and infectious diseases (2 patients). The cause of death
of 5 patients was uncertain.
Predictors of long-term renal outcome and mortality
For analysis of predictors of long-term renal outcome
and mortality, patients requiring permanent haemodialy-
sis within 3 months after admission were censored, leav-
ing 106 patients for analysis. Follow-up BP was
adequately controlled in 33 out of 92 patients (36%) and
uncontrolled in 59 (64%) patients. Black patients had a
higher follow-up BP compared to white patients with a
systolic BP of 153 ± 23 mmHg in black and
140 ± 21 mmHg in white patients (P < 0.01). Diastolic BP
was 96 ± 12 mmHg versus 85 ± 11 mmHg respectively
(P < 0.01). Data on BP during follow-up were incomplete
for 14 out of 106 (13%) patients. Antihypertensive treat-
ment during follow-up consisted of a mean number of
3.3 ± 1.1 drugs. Patients with controlled follow-up BP
used on average 2.9 ± 1.1 antihypertensive drugs, while
patients with uncontrolled BP used on average 3.5 ± 1.1
drugs (P < 0.01).
The primary endpoint was reached by 23 out of 106
(22%) patients after a median follow-up of 67 months
(IQR 28-108 months) with 15 (14%) patients starting
KRT and 8 (8%) patients with an eGFR decline ≥ 50%
(Table 2). Initial serum creatinine ≥ 175 μmol /L and un-
controlled hypertension (BP ≥ 140/90 mmHg) during
follow-up were identified as main predictors of the com-
posite renal outcome (Figure 2) with hazard ratios (HR)Table 2 Patient characteristics at follow-up
Follow-up characteristics
Follow-up time, months, median (IQR )* 67 (28-108)
Died, n (%) 18 (15)
Start of kidney replacement therapy, n (%) 29 (24)
50 % decline of eGFR, n (%) 8 (7)
Systolic blood pressure (mmHg), mean (SD) 146 (23)
Diastolic blood pressure (mmHg), mean (SD) 90 (13)
Blood pressure < 140/ 90 mmHg, n (%) † 33 (36)
BP 140-160/90-100 mmHg, n (%) 42 (46)
BP 160-180/100-110 mmHg, n (%) 12 (13)
BP > 180/100 mmHg, n (%) 5 (5)
ACE-inhibitor or ARB, n (%) 74 (80)
Beta-blocking agent, n (%) 61 (66)
Calcium-antagonist, n (%) 79 (86)
Diuretic, n (%) 64 (70)
Alfa-blocking agent, n (%) 18 (20)
*IQR indicates interquartile range.
† Data on hypertension status and antihypertensive medication during follow-
up were available for 92 patients. Percentages are calculated for a total of 92
patients. One patient used Minoxidil in addition to all 5 antihypertensive
classes listed in the table.of 6.1 (95% CI, 2.2–17) and 4.3 (95% CI, 1.4–14) respect-
ively (Table 3). Patients with a mean follow-up BP > 160/
100 mmHg had a HR of 5.1 (95% CI, 1.4–18) for devel-
oping ESRD (P= 0.01).
Adjustment for primary renovascular and kidney dis-
ease did not materially change the predictive value of
hypertension control on renal outcome. After adjust-
ment HR were 5.2 (95% CI 1.8-15) for patients with ini-
tial serum creatinine ≥ 175 μmol /L and 4.7 (95% CI,
1.3–17) for patients having an average follow-up BP ≥
140/90. The interaction between serum creatinine and
hypertension status was not significant (P= 0.45). Initial
serum creatinine ≥ 175 μmol /L and uncontrolled hyper-
tension during follow-up were also the main predictors
of mortality with HR of 6.3 (95% CI, 2.0–20) and 3.1
(95% CI, 1.0–9.9) respectively.
Discussion
In this study, we show that ESRD remains highly preva-
lent among patients who were previously admitted with
malignant hypertension, with 31% starting KRT or hav-
ing a 50% eGFR decline after a median follow-up of
67 months. Major determinants of long-term renal out-
come were initial serum creatinine values and BP control
during follow-up. Only one controlled hypertensive pa-
tient developed the renal endpoint during follow-up as
opposed to 22 patients with uncontrolled hypertension.
Although previously identified as an important predictor
of renal function improvement [6], the presence of TMA
was not found to predict ESRD.
The incidence rates of ESRD in series describing
patients with malignant hypertension vary from 11% to
53% [2,14,15]. These variations may be due to differ-
ences in follow-up time, population characteristics and
Table 3 Cox regression analyses using backward
elimination method to predict indicators for ESRD during
follow-up
Variables Rank† P-value HR 95% CI
Age 5 0.60 0.9 0.5-1.6
Male 3 0.10 2.5 0.8-7.7
Black 6 0.82 1.1 0.3-3.8
Initial creatinine≥ 175 μmol /L 1 0.00 6.1 2.2-17
Uncontrolled hypertension 2 0.01 4.3 1.4-14
Trombotic microangiopathy 4 0.19 1.9 0.7-5.2
* Renal outcome was defined as a composite of the start of KRT or 50%
decline of eGFR.
†Indicates the rank of elimination in stepwise backward Cox regression.
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only patients admitted via the emergency room and
excluded referred patients with malignant hypertension
as they could be more likely to have ESRD. In addition,
because our aim was to assess predictors of long-term
renal outcome, we censored data of the first 3 months
after admission as renal function during this period is
frequently not yet stabilized.
This study demonstrates that the risk of developing
ESRD in patients with malignant hypertension is mark-
edly elevated. For example in the MRFIT trial, only 3%
of patients with severe non-malignant hypertension
(BP ≥ 210/120 mmHg) developed ESRD after 16 years
[16]. However, patients with evidence of end-organ
damage including renal dysfunction (serum
creatinine > 177 μmol/L) were excluded from the
MRFIT trial. Therefore, differences in baseline renal
function may account for the much higher incidence
of ESRD in patients with malignant hypertension, who
by definition display evidence of end-organ damage in-
cluding renal damage. Besides causing acute renal
damage, malignant hypertension may also reflect diffi-
culty to regulate blood pressure in individuals on the
long-term as placebo-controlled randomized clinical
trials performed decades ago, showed that antihyper-
tensive treatment effectively prevented progression of
essential hypertension to malignant hypertension
[17,18]. In addition, non-compliance to antihyperten-
sive treatment and the lack of insurance and access to
primary health care was observed more frequently in
patients with severe and malignant hypertension [19].
In a previous report we showed that non-compliance
to antihypertensive treatment and lack of medical in-
surance were also observed frequently in our popula-
tion, particularly among ethnic minorities [3]. Our
observation that patients with uncontrolled BP on
follow-up had more antihypertensive drugs compared
to those with controlled hypertension could be an in-
dication of non-compliance. However, average BP was
calculated for the complete follow-up period, whereasdata on antihypertensive drugs represent the last
known treatment. The higher number of antihyperten-
sive drugs could therefore also reflect an effort to con-
trol higher BP values earlier in the follow-up period.
Finally, in addition to differences in baseline renal
function and long-term blood pressure control, the
increased risk of developing ESRD in malignant hyper-
tension might be attributable to endothelial dysfunction.
While having similar blood pressure values, patients
who previously suffered from malignant hypertension
have been shown to display more pronounced endothe-
lial dysfunction as compared to patients with high-risk
(non-malignant) hypertension [20].
The potential effect of BP control on long-term renal
outcome in malignant hypertension has been described
previously in two small case-series from the 1980s in-
cluding a total of 14 patients [21,22]. However, as BP
control was achieved in almost all patients in these two
case-series the potential benefit of BP lowering therapy
on progression of ESRD could not be established. In our
series, patients with uncontrolled hypertension (BP ≥
140/90 mmHg) had a 4.3 fold higher risk of developing
ESRD compared to patients in whom BP was controlled.
Patients with more severe hypertension (> 160/
100 mmHg) during follow-up had a 5.1 fold higher risk
of ESRD. It is conceivable that the propensity to develop
ESRD in those with uncontrolled hypertension may be
due to hyperperfusion of remaining nephrons in those
with renal damage during the acute phase. This is also
exemplified by the fact that renal function, while often
improving after the initial phase, does not fully recover
[6], suggesting residual renal damage.
There was no interaction between hypertension status
and renal function at admission suggesting that the pres-
ence of renal dysfunction was not an important deter-
minant of hypertension status. Several studies including
our own have outlined the potential recovery of renal
function in patients who were admitted with malignant
hypertension after institution of BP lowering therapy
[11,12,23]. In the current analysis, the presence of TMA
as evidence of vascular damage, did not predict long-
term renal outcome suggesting that the detrimental, but
potentially reversible effect of TMA had no negative ef-
fect on long-term renal outcome.
This study has both strengths and limitations.
Strengths include the contribution of clinically relevant
and previously unavailable data on long-term renal out-
come of an unselected, well described and relatively
large cohort of patients with malignant hypertension.
Limitations include its retrospective nature and conse-
quently the possibility of coding errors. However, a sen-
sitivity analysis showed that no patients with malignant
hypertension who visited the emergency room between
1992–2008 were missed. Secondly, follow-up data on BP
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(13%), which may have influenced the association be-
tween hypertension status and ESRD. However baseline
characteristics of patients who lacked complete BP data
were not different with regard to initial serum creatinine,
blood pressure values and need for KRT (data not
shown). Thirdly, analysis of the predictive value of
follow-up proteinuria in this study was hampered by dif-
ferences in testing methods for urinary protein excre-
tion. Also, the reason for performing urine analysis in
the follow-up was subject to bias by indication, as it was
more frequently done in patients showing progressive
renal function decline. Finally, a separate analysis could
not be performed for patients with primary renovascular
and kidney disease because of the limited number of
patients. However, Cox regression analysis revealed simi-
lar results after exclusion of these patients (data not
shown). Although ESRD did not occur significantly more
often in patients with than without renovascular and
kidney disease, this study may have been underpowered
to demonstrate clinically relevant differences in renal
outcome.
Conclusions
Patients with malignant hypertension display a markedly
elevated risk for developing ESRD after the acute phase.
BP control during follow-up was strongly associated with
the risk of progression to ESRD, prompting to adequate
blood pressure regulation for improving long-term renal
outcome in these patients.
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